Chuikyo Agrees to Exempt PD-1/PD-L1, JAK Classes from Spillover Re-Pricing

Japan’s all-powerful reimbursement policy panel has agreed to exclude a total of 14 compounds in the class of PD-1/PD-L1 inhibitors and JAK inhibitors from the so-called “spillover” price cuts under the market expansion re-pricing mechanism. The Central Social Insurance Medical...read more